Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,647 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,647 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06331585 | Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of… | Phase 2 | withdrawn | Mar 26, 2024 | Hetian District People's Hospital | work commitments | Other (stated, no rule matched) |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | Phase 1 / Phase 2 | terminated | Feb 2, 2023 | iOx Therapeutics | Prioritization of other pipeline assets. No safety or efficacy issues were observed. | Safety / toxicity |
| NCT02954991 | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab… | Phase 2 | terminated | Nov 4, 2016 | Mirati Therapeutics Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT04772053 | Molecular Disease Characterization Initiative (MDCI) | Phase 2 | terminated | Feb 26, 2021 | GlaxoSmithKline | The study was terminated for reasons pertaining to feasibility | Other (stated, no rule matched) |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing… | Phase 2 | terminated | Jul 22, 2019 | National Cancer Institute (NCI) | Study was terminated due to slow accrual. | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | N/A | withdrawn | Jun 9, 2022 | Ohio State University Comprehensive Cancer Center | Funding lapse | Funding |
| NCT02920996 | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | Phase 2 | terminated | Sep 30, 2016 | Dana-Farber Cancer Institute | Funding was pulled | Funding |
| NCT03472560 | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or… | Phase 2 | terminated | Mar 21, 2018 | Pfizer | The study was terminated since there was no need for further safety or efficacy data to be… | Safety / toxicity |
| NCT03400748 | ANET Electrosurgery Applicator Pilot Evaluation Study | N/A | terminated | Jan 17, 2018 | Olympus Corporation of the Americas | business reason | Sponsor / business decision |
| NCT03866980 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung… | Phase 3 | terminated | Mar 7, 2019 | Akeso | corporate strategy adjustment | Sponsor / business decision |
| NCT00310232 | Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20) | Phase 3 | terminated | Apr 3, 2006 | Ontario Clinical Oncology Group (OCOG) | Recommendation of DSMB for safety issue, increased mortality with study drug. | Safety / toxicity |
| NCT04610658 | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | Phase 1 | terminated | Oct 30, 2020 | H. Lee Moffitt Cancer Center and Research Institute | DLTs | Other (stated, no rule matched) |
| NCT03699956 | RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or…(REPLATINUM) | Phase 3 | terminated | Oct 9, 2018 | EpicentRx, Inc. | RRx-001 will be studied under a new global, phase 3 clinical trial | Other (stated, no rule matched) |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT05705466 | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and… | Phase 1 / Phase 2 | withdrawn | Jan 30, 2023 | Kartos Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to… | Phase 1 | terminated | May 20, 2020 | Mersana Therapeutics | discontinued development program | Other (stated, no rule matched) |
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer… | Phase 2 | terminated | Oct 30, 2020 | Jeffrey Clarke | Lack of Enrollment | Enrollment / accrual |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or…(SUMMIT) | Phase 2 | terminated | Oct 1, 2013 | Puma Biotechnology, Inc. | The study was terminated to align with the sponsor's current development plans for neratinib. The… | Safety / toxicity |
| NCT04102436 | Non-Viral TCR Gene Therapy | Phase 2 | withdrawn | Sep 25, 2019 | National Cancer Institute (NCI) | Difficulty with availability of GLP-grade reagents for manufacturing. | Drug supply |
| NCT04923802 | Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)(MOTIVATION) | — | terminated | Jun 11, 2021 | GeneCast Biotechnology Co., Ltd. | Unable to recruit sufficient numbers of patients | Enrollment / accrual |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2… | Phase 1 | terminated | Nov 16, 2021 | HiberCell, Inc. | sponsor decision | Sponsor / business decision |
| NCT04352413 | A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based… | Phase 2 | terminated | Apr 20, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT04816214 | Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in…(GEOMETRY-E) | Phase 3 | terminated | Mar 25, 2021 | Novartis Pharmaceuticals | Novartis decided to terminate the study based on a business consideration and not related with any… | Safety / toxicity |
| NCT06052423 | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 25, 2023 | Hansoh BioMedical R&D Company | Research and development strategy adjustment. | Sponsor / business decision |
| NCT02759679 | Canine-Assisted Profiling of Lung Cancer From Human Breath | N/A | terminated | May 3, 2016 | Haukeland University Hospital | not stated | Not stated |
| NCT03403361 | Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of… | N/A | terminated | Jan 18, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in… | Phase 1 / Phase 2 | terminated | Oct 29, 2021 | NKGen Biotech, Inc. | Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best… | Other (stated, no rule matched) |
| NCT02579005 | Radio-Immuno-Modulation in Lung Cancer(RIM) | Phase 1 | suspended | Oct 19, 2015 | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Lack of ressources | Other (stated, no rule matched) |
| NCT03190239 | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced…(XQonc-007) | Phase 2 | withdrawn | Jun 16, 2017 | Xinqiao Hospital of Chongqing | abandon | Other (stated, no rule matched) |
| NCT03257722 | Pembrolizumab + Idelalisib for Lung Cancer Study(PIL) | Phase 1 / Phase 2 | terminated | Aug 22, 2017 | Asha Nayak | The study was terminated due to poor accrual. | Enrollment / accrual |
| NCT03792503 | Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small… | Phase 4 | withdrawn | Jan 3, 2019 | Xinqiao Hospital of Chongqing | abandon | Other (stated, no rule matched) |
| NCT04491084 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy(FLT3) | Phase 1 / Phase 2 | terminated | Jul 29, 2020 | Albert Einstein College of Medicine | Low accrual | Enrollment / accrual |
| NCT05703555 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701(INTRUSION) | Phase 2 | withdrawn | Jan 30, 2023 | Erasmus Medical Center | Due to the decision to discontinue the global clinical development program of tusamitamab ravtansine | Other (stated, no rule matched) |
| NCT03818776 | Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC | Early Phase 1 | terminated | Jan 28, 2019 | Case Comprehensive Cancer Center | Safety | Safety / toxicity |
| NCT05408871 | Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head… | Phase 1 | terminated | Jun 7, 2022 | Yale University | PI changed institutions | Other (stated, no rule matched) |
| NCT02654587 | OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune…(ATALANTE-1) | Phase 3 | terminated | Jan 13, 2016 | OSE Immunotherapeutics | due to COVID-19 | COVID-19 / pandemic |
| NCT04676386 | Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based…(BEACON-LUNG) | — | terminated | Dec 21, 2020 | Addario Lung Cancer Medical Institute | Recruitment futility | Efficacy / futility |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | Phase 1 / Phase 2 | terminated | May 11, 2016 | Cambridge University Hospitals NHS Foundation Trust | Slow recruitment | Enrollment / accrual |
| NCT00617656 | Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With…(BREC) | Phase 3 | terminated | Feb 18, 2008 | Spanish Lung Cancer Group | No safety reasons. Interim analysis shows that the hypothesis superiority of the experimental arm… | Safety / toxicity |
| NCT05176925 | Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent… | Phase 2 | terminated | Jan 4, 2022 | Fudan University | The trial was terminated per sponsor recommendation | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT05848843 | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung… | Phase 1 | withdrawn | May 8, 2023 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT03966807 | Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting for Actively… | — | terminated | May 29, 2019 | Indiana University | Per institutional and PI recommendation | Other (stated, no rule matched) |
| NCT04524195 | PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Aug 24, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study is terminated because the PI left the institution. | Investigator |
| NCT03840902 | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | terminated | Feb 15, 2019 | EMD Serono Research & Development Institute, Inc. | Based on recommendations by an external Independent data Monitoring Committee (IDMC), Sponsor… | Efficacy / futility |
| NCT05088967 | Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in… | Phase 1 | terminated | Oct 22, 2021 | Innovent Biologics (Suzhou) Co. Ltd. | Development strategy adjustment | Sponsor / business decision |
| NCT02502318 | Medicoeconomic Evaluation of Two Surgical Techniques for Lobectomy in the Lung Cancer(LungSco01) | N/A | terminated | Jul 20, 2015 | Centre Hospitalier Universitaire Dijon | lack of inclusions | Other (stated, no rule matched) |
| NCT03492801 | Collection of Blood Samples in Patients With Non-small Cell Lung Cancer | — | terminated | Apr 10, 2018 | University of Southern California | Insufficient accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 25, 2024source: clinicaltrials